We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Affymetrix Licenses Microfluidics Technology

By Biotechdaily staff writers
Posted on 06 May 2005
A nonexclusive license to use a portion of its microfluidics patent estate with the GeneChip microarray technologies of Affymetrix, Inc. More...
(Santa Clara, CA, USA), has been granted by Caliper Life Sciences, Inc. (Hopkinton, MA, USA).

The license extends to the manufacture and sale of GeneChip brand products in all areas of application, including research, diagnostics, and applied genomics applications. In exchange for the license, Affymetrix will pay upfront licensing fees and royalties on future products covered under the agreement. Further financial details were not disclosed.

The scope of the license agreement includes nucleic acid processing and handling associated with GeneChip arrays but excludes the right to use LabChip technology with respect to products intended primarily to perform nucleic acid separations as a discrete, nonintegrated quality control step. Caliper Life Sciences uses its advanced liquid handling and LabChip technologies to create tools that accelerate drug discovery, enable diagnosis of disease, and facilitate scientific research.

"The potential for merging two technologies on the forefront of life science innovation represents an important option for us,” said Alan Sherr, director of licensing for Affymetrix. "We have worked successfully with Caliper as a partner for a year now, and are pleased to be able to extend the scope of our relationship with Caliper to this new area of potential value and importance to Affymetrix' customers.”

Scientists at Affymetrix invented the world's first microarray in 1989 and began selling the first commercial microarry in 1994. The company's patented photolithographic manufacturing process provides the most information capacity available today on an array.





Related Links:
Affymetrix
Caliper Life Sciences

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
Hematology Consumables
Bioblood Devices
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.